Adult Dosing

Condylomata acuminata

• Recommended dose: 0.05 mL (250,000 IU) IV per wart 2 times/week for up to 8 weeks
• Max: 0.5 mL (2.5 million IU)/treatment session

• Inject into the base of each wart using a 30 gauge needle
• For large warts, inject at several points around the periphery of the wart, using a total dose of 0.05 mL/wart
• No further therapy should be administered for 3 months after the initial 8-week course of treatment unless warts enlarge or new warts appear

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Intralesional treatment of refractory or recurring external condylomata acuminata in patients 18 yrs of age

• Hypersensitivity to any of the ingredients of the product
• Anaphylactic sensitivity to mouse immunoglobulin (IgG), egg protein, or neomycin

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Exercise caution in patients with debilitating medical conditions such as cardiovascular disease, severe pulmonary disease, or diabetes mellitus with ketoacidosis as therapy may be associated with fever and other flu-like symptoms
• Discontinue therapy and initiate appropriate medical therapy if acute, serious hypersensitivity reactions occur
• Therapy may carry a risk of transmitting infectious agents such as viruses and Creutzfeldt-Jakob disease (CJD) agent because this product is derived from human blood
• Interferon products are not interchangeable as the manufacturing process, strength, and type of interferon may vary for different interferon formulations

Cautions: Use cautiously in

• Coagulation disorders
• Severe myelosuppression
• Seizure disorders

Supplemental Patient Information

• Inform patients of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis; advise them to contact their physicians if these symptoms occur
• Caution patients not to interchange brands of interferon without consulting their physicians, as it may require change is dosage

Pregnancy Category:C

Breastfeeding: It is unknown whether interferon alfa-n3 is excreted in human milk. As many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or treatment, analyzing the importance of the drug to the mother and the potential risks to the infant.

• CNS: Dizziness, headache, insomnia
• MUSC: Myalgias, arthralgia, back pain
• MISC: Flu-like symptoms, fever, chills, fatigue, malaise

• Immunomodulator; binds to specific membrane receptors on cell surfaces, initiating induction of protein synthesis, promoting inhibition of viral replication, suppression of cell proliferation, and/or immunomodulation activities
• Absorption: Unknown
• Metabolism: Unknown
• Half-life: Unknown

US Trade Name(s)

• Alferon N Injection

US Availability

Alferon N Injection

• INJ: 5 MIU/vial

Canadian Trade Name(s)

• N/A

Canadian Availability

UK Trade Name(s)

• N/A

UK Availability

Immunologic

Immunomodulators

Immunologic

Interferons